Selection of transduced CD34+ progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectors.
The gene transfer efficiency of human hematopoietic stem cells is still inadequate for efficient gene therapy of most disorders. To overcome this problem, a selectable retroviral vector system for gene therapy has been developed for gene therapy of Gaucher disease. We constructed a bicistronic retroviral vector containing the human glucocerebrosidase (GC) cDNA and the human small cell surface antigen CD24 (243 bp). Expression of both cDNAs was controlled by the long terminal repeat enhancer/promoter of the Molony murine leukemia virus. The CD24 selectable marker was placed downstream of the GC cDNA and its translation was enhanced by inclusion of the long 5' untranslated region of encephalomyocarditis virus internal ribosomal entry site. Virus-producing GP+envAM12 cells were created by multiple supernatant transductions to create vector producer cells. The vector LGEC has a high titer and can drive expression of GC and the cell surface antigen CD24 simultaneously in transduced NIH 3T3 cells and Gaucher skin fibroblasts. These transduced cells have been successfully separated from untransduced cells by fluorescence-activated cell sorting, based on cell surface expression of CD24. Transduced and sorted NIH 3T3 cells showed higher GC enzyme activity than the unsorted population, demonstrating coordinated expression of both genes. Fibroblasts from Gaucher patients were transduced and sorted for CD24 expression, and GC enzyme activity was measured. The transduced sorted Gaucher fibroblasts had a marked increase in enzyme activity (149%) compared with virgin Gaucher fibroblasts (17% of normal GC enzyme activity). Efficient transduction of CD34+ hematopoietic progenitors (20-40%) was accomplished and fluorescence-activated cell sorted CD24(+)-expressing progenitors generated colonies, all of which (100%) were vector positive. The sorted, CD24-expressing progenitors generated erythroid burst-forming units, colony-forming units (CFU)-granulocyte, CFU-macrophage, CFU-granulocyte/macrophage, and CFU-mix hematopoietic colonies, demonstrating their ability to differentiate into these myeloid lineages in vitro. The transduced, sorted progenitors raised the GC enzyme levels in their progeny cells manyfold compared with untransduced CD34+ progenitors. Collectively, this demonstrates the development of high titer, selectable bicistronic vectors that allow isolation of transduced hematopoietic progenitors and cells that have been metabolically corrected.
Migita
M
M
Molecular and Medical Genetics Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
Medin
J A
JA
Pawliuk
R
R
Jacobson
S
S
Nagle
J W
JW
Anderson
S
S
Amiri
M
M
Humphries
R K
RK
Karlsson
S
S
D016475:3T3 Cells; D000818:Animals; D015703:Antigens, CD / Q000096:biosynthesis / Q000235:genetics*; D018952:Antigens, CD34 / Q000276:immunology*; D001483:Base Sequence; D051927:CD24 Antigen; D003114:Colony-Forming Units Assay; D017931:DNA Primers; D004742:Enhancer Elements, Genetic; D005776:Gaucher Disease / Q000235:genetics* / Q000276:immunology* / Q000628:therapy; D015870:Gene Expression; D005796:Genes; D015316:Genetic Therapy; D005822:Genetic Vectors; D005962:Glucosylceramidase / Q000096:biosynthesis / Q000235:genetics*; D006412:Hematopoietic Stem Cells / Q000276:immunology* / Q000502:physiology; D006801:Humans; D008562:Membrane Glycoproteins; D051379:Mice; D008969:Molecular Sequence Data; D008979:Moloney murine leukemia virus; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic; D012091:Repetitive Sequences, Nucleic Acid; D014161:Transduction, Genetic
D015703:Antigens, CD; D018952:Antigens, CD34; D051927:CD24 Antigen; C497889:CD24 protein, human; C497890:Cd24a protein, mouse; D017931:DNA Primers; D008562:Membrane Glycoproteins; D005962:Glucosylceramidase